Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 5/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.46 |
| ▸ | BCHE | P06276 | 5/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291276 | 0.92 | PPARA (0.48) | CYP4F2CYP4A11FFAR4FFAR1MAOB | |
| SCHEMBL2287384 | 0.88 | SOD1 (0.54) | CYP4F2CYP4A11FFAR4FFAR1MAOB | |
| SCHEMBL2292282 | 0.83 | FFAR4 (0.65) | FFAR4FFAR1MAOBPARP10 | |
| SCHEMBL28035930 | 0.82 | CYP4F2 (0.51) | CYP4F2CYP4A11MAOBABCB1BCHE | |
| SCHEMBL2293337 | 0.81 | MAOB (0.45) | CYP4F2CYP4A11FFAR4FFAR1MAOB | |
| SCHEMBL327570 | 0.81 | CYP4F2 (0.70) | CYP4F2CYP4A11FFAR1MAOBABCB1 | |
| SCHEMBL2292614 | 0.79 | MAOA (0.47) | CYP4F2CYP4A11MAOBABCB1BCHE | |
| SCHEMBL2290158 | 0.78 | MAOB (0.54) | FFAR4FFAR1MAOBDRD2PARP10 | |
| SCHEMBL2292356 | 0.78 | FFAR4 (0.52) | FFAR4FFAR1ABCB1HTR1ADRD2 | |
| SCHEMBL2290287 | 0.78 | FFAR4 (0.55) | FFAR4FFAR1ABCB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2149545-B1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-7994367-B2 | Method for producing benzaldehyde compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-09 | — | — | US | disclosed |
| US-20100210879-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-08-19 | — | — | US | disclosed |
| EP-2149545-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210879-A1 | METHOD FOR PRODUCING BENZALDEHYDE COMPOUND | NQO1, C9, TRPA1 | CYP4F2 276/4885CYP4A11 1597/4885FFAR4 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.